TAMPA, FL / ACCESSWIRE / July 12, 2021 / TRxADE HEALTH, INC. (NASDAQ:MEDS) a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey and patient engagement in the U.S., will release financial results for the second quarter 2021, after market close on July 26, 2021.
Management will host a conference call on Monday, July 26, 2021 at 5:00 p.m. Eastern time to discuss TRxADE HEALTH’s second quarter 2021 financial results. The call will conclude with Q&A from participants.
To participate, please use the following information:
Q2 2021 Conference Call and Webcast
Date: Monday, July 26, 2021
Time: 5:00 p.m. Eastern time
U.S. Dial-in: 1-877-425-9470
International Dial-in: 1-201-389-0878
Conference ID: 13720923
Webcast: http://public.viavid.com/index.php?id=145434
Please dial in at least 10 minutes before the start of the call to ensure timely participation.
A playback of the call will be available through August 26, 2021. To listen, call 1-844-512-2921 within the United States or 1-412-317-6671 when calling internationally and enter replay pin number 13720923. A webcast will also be available for 30 days on the IR section of the TRxADE HEALTH website or by clicking the webcast link above.
About TRxADE HEALTH, INC.
TRxADE HEALTH (NASDAQ:MEDS) is a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey and patient engagement in the U.S. The Company operates the TRxADE drug procurement marketplace serving a total of 12,100+ members nationwide, fostering price transparency and under the Bonum Health brand, offering patient centric telehealth services. For info on TRxADE HEALTH, please visit the Company’s IR website at investors.trxadegroup.com.
Investor Relations:
Lucas Zimmerman
Director
MZ Group – MZ North America
(949) 259-4987
MEDS@mzgroup.us
www.mzgroup.us
SOURCE: TRxADE Group, Inc.
View source version on accesswire.com:
https://www.accesswire.com/654993/TRxADE-HEALTH-to-Report-Second-Quarter-2021-Financial-Results-on-Monday-July-26th-at-430-pm-Eastern-Time
At 14-months median follow-up in the pivotal trial, 50% of patients achieved a complete response…
Objective response rate of 69.2% observed in heavily pretreated patient population including patients with BTK…
The study met its primary endpoint of overall survival with a 41% reduction in the…
DENVER, CO / ACCESSWIRE / June 15, 2024 / Each year over 120,000 Coloradans are…
REYKJAVIK, Iceland, June 15, 2024 /PRNewswire/ -- In a recent display of global baking talent,…
– ENERGIZE is the First Study to Demonstrate Efficacy of an Oral Treatment for Non-Transfusion-Dependent Alpha-…